Eyes Openers
  • World News
  • Business
  • Stocks
  • Politics
  • World News
  • Business
  • Stocks
  • Politics

Eyes Openers

Business

Cambridge warns UK must scale up investment to turn spin-outs into global success stories

by May 27, 2025
May 27, 2025
Cambridge warns UK must scale up investment to turn spin-outs into global success stories

University of Cambridge leaders have issued a stark warning that the UK risks falling behind in the race to commercialise world-class research unless it does more to support academic spin-out companies struggling to scale.

Speaking at a London showcase of Cambridge’s most promising spin-outs, university figures and venture capitalists said that while Britain remains a hub of scientific excellence, it lacks the investment firepower and infrastructure needed to turn breakthrough research into category-defining global businesses.

“The world isn’t waiting for UK and European science to commercialise,” said Gerard Grech (pictured), managing director of Founders, a Cambridge initiative to boost entrepreneurial growth. “Founders in Silicon Valley, Shenzhen and Bangalore are already building, and very, very quickly. The question is: can European universities match that pace without losing the depth that makes our research world-class?”

Grech said that many of the best commercial opportunities emerge when university science interacts with bold capital, adding: “This is where real innovation happens.”

Cambridge’s vice-chancellor, Deborah Prentice, highlighted the university’s strong track record in spin-out formation. Last year, Cambridge spin-outs raised more than $2 billion, and the institution now produces more spin-outs per capita than any other UK university.

“Cambridge is by many measures the highest-performing innovation ecosystem in Europe,” she said. “International investors, large companies and world-class scientists are recognising that we’re punching above our weight — but we need to go further.”

However, the ability to grow these ventures into globally competitive firms remains a major hurdle. Data from Dealroom cited during the event showed that while Cambridge has a healthy pipeline of start-ups with up to $10 million in venture capital, the number of firms that go on to raise $100 million or more remains significantly lower than in Silicon Valley.

“That is the problem. It is as simple as that,” said Suranga Chandratillake, general partner at Balderton Capital. “You can build so much of a business with $10 million, $20 million, or $30 million. But you need hundreds of millions to build truly global, category-defining companies. And we just don’t have enough companies raising that kind of money.”

The showcase featured pitches from several early-stage, high-impact ventures looking to address complex medical problems. Prodromic, for example, is developing predictive diagnostics that could detect the early onset of brain diseases like dementia. Gastrobody Therapeutics is working on ingestible, stable antibodies for treating gastrointestinal diseases such as Crohn’s, potentially eliminating the need for injections.

Such innovations demonstrate the commercial potential sitting within UK universities, but investors and academics alike warned that unless Britain finds a way to provide follow-on capital at scale, these businesses may never realise their full potential — or may end up relocating abroad.

The message from Cambridge was clear: if the UK wants to turn scientific leadership into economic leadership, it must urgently improve its ability to fund, grow and retain its most promising ventures.

With international capital accelerating elsewhere, and breakthrough research already happening on British soil, the missing piece is not invention — it’s investment at scale.

Read more:
Cambridge warns UK must scale up investment to turn spin-outs into global success stories

previous post
BGF pledges £3 billion to support UK growth businesses, with £300 million aimed at female-led firms
next post
Oxford Brain Diagnostics to roll out revolutionary dementia technology following UK and US regulatory approvals

Related Posts

The Future of Cloud Gaming and Its Challenges

May 19, 2025

Business Travel & Back Pain: How the Right...

May 25, 2025

UK car production slumps to lowest April levels...

May 29, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Popular Posts

    • 1

      Bolder maritime security forged by Manila and Seoul for the Indo-Pacific region

      September 24, 2024
    • 2

      Floods in South Asia expose gaps in regional climate cooperation

      October 10, 2024
    • A GOP operative accused a monastery of voter fraud. Nuns fought back.

      October 24, 2024
    • 4

      South Korea court begins review of Yoon impeachment

      December 16, 2024
    • 5

      Bill to rewrite Indigenous rights brings tens of thousands of protesters to New Zealand’s parliament

      November 19, 2024

    Categories

    • Business (292)
    • Politics (20)
    • Stocks (80)
    • World News (21)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: EyesOpeners.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 EyesOpeners.com | All Rights Reserved